Lipocine Inc (LPCN)

[grizzly2314]

From Matt over at Yahoo finance:

"did anyone listen to the webcast from Oppenheimer? I thought Dr. Patel did very well. Key takeaways that I had. 1. He does not seem concerned with secondary endpoints on LPCN1021 studies. All testosterone products on the market have some variation in this regard and the secondary endpoint targets - should not lead to rejection. 2. He was really excited about LPCN1107 and the fact that it is more effective than existing Makena. He said existing Makena shots are 30 - 40% effective in reducing pre-term birth, and the 1107 would do better than that. Third, he indicated that partnerships for distribution are ongoing conversations. again I thought it was a very positive presentation and we'll done."


Considering this is an open label trial and the fact that Dr. Patel is so positive tells me that the trial is going good so far!